Key Highlights
- Enovis (NYSE:ENOV) was quoted 17.22% higher at about USD 28.63 in trading on November 5, 2026, per published market data, after third-quarter results.
- Net sales were USD 558.7 million, up 2% reported and about 5% organic, with adjusted EPS of USD 0.88 against USD 0.75 a year earlier.
- Adjusted EBITDA was USD 103.5 million, an 18.5% margin, and 2026 adjusted EPS guidance rose to USD 3.58 to USD 3.79.
- The board approved a new USD 200 million share repurchase authorization and the company agreed to acquire eCential Robotics.
Results, Guidance and a Bigger Buyback
Enovis (NYSE:ENOV) released third-quarter 2026 results for the quarter ended October 2, 2026, and the shares were quoted 17.22% higher at about USD 28.63 in trading on November 5, 2026, per published market data. Net sales were USD 558.7 million. Organic growth was about 5% per the release text. Reconstructive sales rose 6%, while Prevention and Recovery fell 2% reported and rose 3% organically. Adjusted EBITDA was USD 103.5 million, an 18.5% margin, against USD 94.8 million and 17.3% a year earlier. Full-year adjusted EBITDA guidance moved to USD 428 million to USD 438 million from USD 425 million to USD 435 million, adjusted EPS to USD 3.58 to USD 3.79, and Revenue to USD 2.32 billion to USD 2.35 billion. The board replaced a USD 100 million buyback with a USD 200 million authorization.
Profit Quality, Cash and Debt
GAAP results were thin. Net Income was USD 3.4 million, and GAAP EPS from continuing operations was USD 0.02. Adjusted EPS of USD 0.88 strips out items such as amortization, integration costs related to the Lima Acquisition and separation costs, so investors should weigh both. Cash and equivalents fell to USD 13.0 million from USD 36.4 million at year-end 2025, while total Debt was USD 1,258.3 million. Nine-month Operating Cash Flow was USD 170.5 million against capital expenditures of USD 133.2 million, reflecting heavy Investment in instruments used with its implants. Free cash flow conversion is expected at 25% or higher. Chief Executive Damien McDonald described continued progress in the innovation-led strategy and said the environment remains dynamic, with Volatility and cost Inflation in many markets.
Risks and What to Watch
Leverage is the central risk: with debt above USD 1.2 billion and only USD 13.0 million of cash, a buyback and the planned purchase of eCential Robotics both lean on operating cash flow and Credit lines. Interest costs rise if rates stay high. Medical device makers also face pricing pressure from hospitals, procedure Volume swings, Supply chain costs and integration risk. Published market data puts the company at about USD 1.65 billion in market value, and volume was light relative to its average, so a quoted 17.22% gain may not hold. A trailing GAAP loss figure in published market data looks distorted by past charges and is not used here. Next watch the fourth-quarter report, integration of the acquisition and buyback pace.
Where Things Stand
Enovis (NYSE:ENOV) rose 17.22% because the quarter showed organic growth near 5%, a higher adjusted margin, raised 2026 guidance and a doubled buyback, which together eased fears of a weaker outlook. The case is not clean: GAAP profit was only USD 3.4 million and debt is high against thin cash. The quoted move is intraday and can reverse. The next test is delivery of the raised adjusted EPS range while Leverage is managed.






Please wait processing your request...